STIM vs ABSI vs RXRX vs ELMD

For growth investors, Neuronetics, Inc.

(STIM) is the stronger pick with 99. 2% revenue growth year-over-year, versus -38. 2% for Absci Corporation (ABSI). Electromed, Inc. (ELMD) offers the better valuation at 31. 2x trailing P/E (24. 4x forward), making it the more compelling value choice. Analysts rate Neuronetics, Inc. (STIM) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Electromed, Inc.

(ELMD) delivered a total return of +178. 1%, compared to -88. 2% for Recursion Pharmaceuticals, Inc. (RXRX). Over 10 years, the gap is even starker: ELMD returned +482. 6% versus STIM's -93. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Electromed, Inc.

(ELMD) is the lower-risk stock at 1. 03β versus Recursion Pharmaceuticals, Inc. 's 3. 18β — meaning RXRX is approximately 209% more volatile than ELMD relative to the S&P 500. On balance sheet safety, Electromed, Inc. (ELMD) carries a lower debt/equity ratio of 0% versus 3% for Neuronetics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Neuronetics, Inc.

(STIM) is pulling ahead at 99. 2% versus -38. 2% for Absci Corporation (ABSI). On earnings-per-share growth, the picture is similar: Neuronetics, Inc. grew EPS 57. 2% year-over-year, compared to 10. 6% for Absci Corporation. Over a 3-year CAGR, STIM leads at 31. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Electromed, Inc.

(ELMD) is the more profitable company, earning 11. 8% net margin versus -41. 1% for Absci Corporation — meaning it keeps 11. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ELMD leads at 15. 1% versus -44. 5% for ABSI. At the gross margin level — before operating expenses — ELMD leads at 78. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for STIM: 334.

8% to $8. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Electromed, Inc.

(ELMD) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 03), +482. 6% 10Y return). Recursion Pharmaceuticals, Inc. (RXRX) carries a higher beta of 3. 18 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ELMD: +482. 6%, RXRX: -81. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: STIM is a small-cap high-growth stock; ABSI is a small-cap quality compounder stock; RXRX is a small-cap high-growth stock; ELMD is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.